Poster Presentation
![](/wp-content/uploads/2021/12/blue-accent-full.png)
![](/wp-content/uploads/2021/12/green-accent-full.png)
![](/wp-content/uploads/2021/12/red-accent-full.png)
Publications
Poster Presentation
CA125 immunosuppresses CD19/CD20 antibodies and bispecifics, while NAV-006 escapes this mechanism
Publication
NAV-001, antibody-drug conjugate targeting mesothelin and counteracting CA125 inhibitory effects
Publication
NAV-003, Bispecific Targeting Mesothelin With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors
Publication
NAV-006, next-gen rituximab with enhanced effector function by counteracting CA125 immunosuppression
Poster Presentation
The ADC NAV-001 targets mesothelin, deploys a novel payload, and is refractory to CA125 inhibition
Poster Presentation
HIO-3, a tumor-produced protein that binds the human IgG1 Fc CH3 domain and suppresses ADCC and CDC
Poster Presentation
NAV-003, Bispecific Targeting Mesothelin With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors
Poster Presentation
BRITE Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression
Publication